NodThera
NodThera is a private biotechnology company focused on the discovery and development of next generation NLRP3 inflammasome inhibitors for the treatment of diseases driven by chronic inflammation. The Company is led by a strong management team that combines a deep understanding of NLRP3 inflammasome inhibition with extensive pharmaceutical experience of drug discovery and development. NodThera is building a pipeline of small molecule NLRP3 inhibitors through a highly differentiated, next generation approach that builds on and enhances existing understanding of NLRP3 biochemistry and its role in inflammation.
Sector
Biopharmaceuticals
Strategies
Capital
Status
Live
Website
www.nodthera.com
Related News
NodThera Demonstrates Reversal of Neuroinflammation and Inflammation in Parkinson’s Disease with Oral NLRP3 Inhibitor
NodThera Charts Obesity Future with First Patients Dosed in Phase 2 RESOLVE-1 Trial of Oral NLRP3 Inflammasome Inhibitor NT-0796
NodThera’s oral NLRP3 inhibitor NT-0796 enhances and sustains weight loss in combination with GLP-1
NodThera announces appointment of Greg Chow as Chief Financial and Business Officer
NodThera’s NLRP3 inhibitor NT-0796 meets primary endpoint of inflammation reversal in Phase Ib/IIa Trial in obese subjects with cardiovascular risk
NodThera announces appointment of Daniel Swisher as Chief Executive Officer
NodThera’s NLRP3 inhibitor NT-0796 reverses neuroinflammation in Parkinson’s disease phase Ib/IIa trial
NodThera publishes preclinical data demonstrating reversal of obesity and inflammation with clinical-stage brain-penetrant NLRP3 inflammasome inhibitors
NodThera is first to demonstrate reduction in neuroinflammation in the clinic with brain penetrant NLRP3 inflammasome inhibitor
NodThera announces positive Phase 1 study readouts for the NLRP3 inflammasome inhibitors NT-0796 and NT-0249
NodThera announces clinical progress for lead NLRP3 inflammasome inhibitors and candidate selection of novel brain-penetrant compound
NodThera Announces Close of $55 Million Series B Financing
NodThera Highlights Significant Progress with Advancement of Lead Development Candidate and Key Additions to Board
NodThera secures £28 million ($40 million) Series A Financing
SofinnovaCapital
The Sofinnova Capital Strategy is our flagship fund, investing as founding or lead investor in early-stage biopharma and medtech start-ups developing groundbreaking therapeutic technologies.
SofinnovaMD Start
The Sofinnova MD Start Strategy is our in-house medtech accelerator focused on creating and launching early-stage medtech companies through hands-on company building.
SofinnovaCrossover
The Sofinnova Crossover Strategy invests in growth-stage biotech and medtech companies that have clinically validated their technologies and are preparing for commercialization.
SofinnovaIndustrial Biotech
Our Industrial Biotech Strategy invests in early-stage sustainable companies across the agriculture, chemicals, food and materials sectors.
SofinnovaTelethon
The Sofinnova Telethon Strategy makes early-stage investments in leading Italian science for the benefit of patients around the world.
SofinnovaDigital Medicine
Our Digital Medicine Strategy backs early-stage techbio and healthtech start-ups at the intersection of biology, data, and computation.
SofinnovaBiovelocita
The Sofinnova Biovelocita Strategy is our biotech accelerator, partnering with leading research organizations to create and build European biotech start-ups.